Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
May 17 2023 - 4:30PM
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology
company dedicated to discovering and developing transformative
treatments to restore and improve hearing and balance, today
announced that Laurence Reid, Ph.D., Chief Executive Officer, will
participate in a fireside chat at the Barclays 2023 Gene Editing
and Gene Therapy Summit on Wednesday, May 24, 2023 at 10:30 a.m.
E.T being held virtually.
A live webcast of the presentation may be accessed by visiting
the Investors section of the Decibel Therapeutics website at
https://ir.decibeltx.com. An archived replay of the webcast will be
available on the Company’s website for approximately 90 days
following the fireside chat.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company
dedicated to discovering and developing transformative treatments
to restore and improve hearing and balance, one of the largest
areas of unmet need in medicine. Decibel has built a proprietary
platform that integrates single-cell genomics and bioinformatic
analyses, precision gene therapy technologies and expertise in
inner ear biology. Decibel is leveraging its platform to advance
gene therapies designed to selectively replace genes for the
treatment of congenital, monogenic hearing loss and to regenerate
inner ear hair cells for the treatment of acquired hearing and
balance disorders. Decibel’s pipeline, including its lead gene
therapy product candidate, DB-OTO, to treat congenital, monogenic
hearing loss, is designed to deliver on our vision of a world in
which the privileges of hearing and balance are available to all.
For more information about Decibel Therapeutics, please visit
www.decibeltx.com or follow us on Twitter.
Investor Contact:Julie SeidelStern Investor
Relations, Inc.julie.seidel@sternir.com212-362-1200
Media Contact:Chris RaileyTen Bridge
CommunicationsChris@tenbridgecommunications.com617-834-0936
Decibel Therapeutics (NASDAQ:DBTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Decibel Therapeutics (NASDAQ:DBTX)
Historical Stock Chart
From Oct 2023 to Oct 2024